Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

Combinations of anticancer therapies with high efficacy and low toxicities are highly sought after. Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vori...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Wissing, Michel D., Mendonca, Janet, Kortenhorst, Madeleine S. Q., Kaelber, Nadine S., Gonzalez, Matthew, Kim, Eunice, Hammers, Hans, van Diest, Paul J., Carducci, Michael A., Kachhap, Sushant K.
التنسيق: Artigo
اللغة:Inglês
منشور في: Federation of American Societies for Experimental Biology 2013
الموضوعات:
Research Communications
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4046181/
https://ncbi.nlm.nih.gov/pubmed/23884428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.12-222893
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة